← TAKEDA PHARMACEUTICAL CO LTD TAK
Market Price
$17.65
Market Cap
$55.60B
P/E Ratio
N/A
Revenue (FY 2026)
↓-1.7% YoY
$4.51T
3-Yr CAGR: 3.8%
Net Income
↓-70,979.1% YoY
-$152.39B
Net Margin: -3.4%
Free Cash Flow
N/A
FCF Yield: N/A
EPS (Diluted)
N/A
Basic: N/A
Return on Equity
Efficiency
-2.1%
ROA: -1.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (TAK)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2014 | — | — | — | — | — | — | — | — | — | — |
| FY 2017 | $1,732,051.0M | — | $1,173,296.0M | $143,346.0M | — | — | — | — | — | — |
| FY 2018 | $1,770,531.0M | +2.2% | $1,274,610.0M | $217,205.0M | +51.5% | — | — | — | — | — |
| FY 2019 | $2,097,224.0M | +18.5% | $1,437,534.0M | $-112.0M | -100.1% | — | — | — | — | — |
| FY 2020 | $3,291,188.0M | +56.9% | $2,201,424.0M | $49.0M | +143.8% | — | — | — | — | — |
| FY 2021 | $3,197,812.0M | -2.8% | $2,203,504.0M | $166.0M | +238.8% | — | — | — | — | — |
| FY 2022 | $3,569,006.0M | +11.6% | $2,462,160.0M | $107.0M | -35.5% | — | — | — | — | — |
| FY 2023 | $4,027,478.0M | +12.8% | $2,783,406.0M | $21.0M | -80.4% | — | — | — | — | — |
| FY 2024 | $4,263,762.0M | +5.9% | $2,837,084.0M | $130.0M | +519.0% | — | — | — | — | — |
| FY 2025 | $4,581,551.0M | +7.5% | $3,001,334.0M | $215.0M | +65.4% | — | — | — | — | — |
| FY 2026 | $4,505,720.0M | -1.7% | $2,934,132.0M | $-152,390.0M | -70,979.1% | — | — | — | — | — |
Valuation
Market Price
$17.65
Market Cap
$55.60B
Enterprise Value
$4.34T
P/E Ratio
N/A
P/B Ratio
0.01
FCF Yield
N/A
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
65.12%
Operating Margin
0.14%
Net Margin
-3.38%
Return on Equity (ROE)
-2.05%
Return on Assets (ROA)
-0.98%
Asset Turnover
0.29x
Revenue 3-Yr CAGR
3.81%
Financial Health & Liquidity
Current Ratio
30.96
Cash Ratio
5.96
Debt / Equity
0.657
Debt / Assets
0.315
Cash & Equivalents
$595.05B
Total Debt
$4.88T
Book Value / Share
$2,326.80
Cash Flow Efficiency
Operating Cash Flow
N/A
Capital Expenditures (CapEx)
$169.55B
Free Cash Flow
N/A
OCF / Revenue
N/A
FCF / Revenue
N/A
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
N/A
EPS (Basic)
N/A
Dividends / Share
N/A
Book Value / Share
$2,326.80
EPS YoY Growth
N/A
Balance Sheet (FY 2026)
Total Assets
$15.51T
Total Liabilities
$8.08T
Stockholders' Equity
$7.43T
Current Assets
$3.09T
Current Liabilities
$99.82B